Caricamento...
Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objective resp...
Salvato in:
| Pubblicato in: | EMBO Mol Med |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6609910/ https://ncbi.nlm.nih.gov/pubmed/31273938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910293 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|